Enrollment Commences in Phase III Clinical Study of Eisai’s BACE Inhibitor E2609 in Early Alzheimer’s Disease

TOKYO Oct 31 2016 JCN Newswire Eisai Co. Ltd. announced today that enrollment has commenced in MISSION AD a Phase III clinical program of the beta secretase cleaving enzyme BACE inhibitor E2609 in…
Read the full story: Bioportfolio Biomarker News